Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00244348

Hepatic Artery Infusion With Oxaliplatin

Hepatic Arterial Infusion of Oxaliplatin Clinical Trial

Status
Withdrawn
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Medical College of Wisconsin · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hepatic artery infusion (HAI) with oxaliplatin (OX), systemic 5 fluorouracil (5FU), and leucovorin (HAI/OX/FU) will be implemented using an interventional radiology technique to obviate the need for initial major surgery (catheter placement) in patients who have unresectable liver metastasis from colorectal cancer. The study goal is to reduce tumor size to make possible a complete resection of all lesions. Secondary goals are to reduce or eliminate the complexity usually associated with HAI, to accomplish most or all of the treatment as an outpatient, to reduce costs, and to avoid the hepatotoxicity associated with HAI/floxuridine (FUDR). Oxaliplatin has been selected because of its ease of use, known toxicology, and established efficacy in colorectal cancer.

Detailed description

After entry qualification and registration patients will undergo hepatic artery catheterization via interventional radiology. The catheter will remain in place for two hours while oxaliplatin is infused and then be removed. This treatment will be followed by a 48 hour infusion of 5FU and leucovorin, generally following the principle of FOLFOX 6. These cycles of therapy will be repeated biweekly for six episodes. Hepatic tumor size will be evaluated by CT scan to determine if resectability has been established as the result of tumor size reduction. If so, the patient will be offered resection of the residual lesions in an effort to achieve long term survival.

Conditions

Interventions

TypeNameDescription
DRUGOxaliplatin (via HAI)
DRUG5 Fluorouracil (systemic)

Timeline

Start date
2005-10-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2005-10-26
Last updated
2015-08-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00244348. Inclusion in this directory is not an endorsement.